Along with knowing more about Alzheimer’s disease, public education needs to openly address the option of not having to live ...
Families waiting for new Alzheimer’s treatments are about to get a wave of data. Eight Phase 3 clinical trials, each testing a different drug or intervention, are scheduled to reach their primary ...
Biogen plans to advance its investigative therapy for people with early Alzheimer's disease following positive trial results and what the biotechnology company says is a consistent body of evidence.
Researchers have identified seven proteins in the blood that could enable better blood tests for Alzheimer's disease. A study shows that using a broader panel of markers provides a clearer picture of ...
A major focus of R&D in the Alzheimer’s disease therapeutic space is preventing the accumulation of amyloid beta.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results